Company: PRME
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0001628280-25-008884
Chunk: 235

Company: Prime Medicine, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 235
---
 issuance costs18,800 — Proceeds from issuance of common stock under the BMS Securities Purchase Agreement — related party38,081 — Proceeds from research and development funding liability6,000 — Proceeds from ESPP offerings837 — Net proceeds from stock option exercises103 655 Net cash provided by financing activities195,876 655 Net change in cash, cash equivalents, and restricted cash141,468 (146,046)Cash, cash equivalents, and restricted cash at beginning of period55,070 201,116 Cash, cash equivalents, and restricted cash at end of period$196,538 $55,070 

The accompanying notes are an integral part of these consolidated financial statements.

F-6

PRIME MEDICINE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWSYear Ended December 31,(in thousands)20242023Reconciliation of cash, cash equivalents and restricted cash:Cash, cash equivalents, and restricted cash at end of period$196,538 $55,070 Less: restricted cash14,062 13,496 Total cash, and cash equivalents$182,476 $41,574 Supplemental cash flow information:Right-of-use assets obtained in exchange for new operating lease liabilities$44,935 $3,265 Decrease in right-of-use assets due to lease termination$— $6,081 Supplemental disclosure of non-cash investing and financing activities:Purchases of property and equipment included in accounts payable and accrued expenses$1,154 $575 

The accompanying notes are an integral part of these consolidated financial statements.

F-7